ImmunoGen Inc. (IMGN)

5.01
NASDAQ : Health Technology
Prev Close 5.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.90 / 13.41
Avg Volume 2.33M
Exchange NASDAQ
Shares Outstanding 149.09M
Market Cap 772.29M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of IMGN July 2019 Options Trading

First Week Of IMGN July 2019 Options Trading

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the July 2019 expiration.

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:...

ImmunoGen Reports Recent Progress And Third Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And Third Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended September 30, 2018.

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 60th ASH Annual Meeting

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 60th ASH Annual Meeting

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company's experimental ADC therapies, IMGN779 and IMGN632, have been...

Interesting IMGN Put And Call Options For December 21st

Interesting IMGN Put And Call Options For December 21st

Investors in ImmunoGen, Inc. saw new options become available this week, for the December 21st expiration.

Oversold Conditions For ImmunoGen (IMGN)

Oversold Conditions For ImmunoGen (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ImmunoGen Presents Initial Data From FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO 2018 Congress

ImmunoGen Presents Initial Data From FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO 2018 Congress

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab...

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2018 Operating Results

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.

ImmunoGen To Present Initial Data From FORWARD II Expansion Cohort Of Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO

ImmunoGen To Present Initial Data From FORWARD II Expansion Cohort Of Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with...

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: 2018...

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: 20 th...

ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference

ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference.

ImmunoGen Reports Recent Progress And Second Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And Second Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended June 30, 2018.

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2018 Operating Results

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.

ImmunoGen Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their...

IMGN Crosses Above Average Analyst Target

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $10.75, changing hands for $11.21/share.

ImmunoGen Announces FDA Fast Track Designation For Mirvetuximab Soravtansine In Patients With Platinum-Resistant Ovarian Cancer

ImmunoGen Announces FDA Fast Track Designation For Mirvetuximab Soravtansine In Patients With Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.

ImmunoGen Announces Closing Of Public Offering Of Common Stock

ImmunoGen Announces Closing Of Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock...

ImmunoGen Announces Pricing Of Upsized Public Offering Of Common Stock

ImmunoGen Announces Pricing Of Upsized Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of...

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common...

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Interesting IMGN Put And Call Options For January 2019

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the January 2019 expiration.

ImmunoGen Announces Positive Findings From The FORWARD II Study Of Mirvetuximab Soravtansine Combination Regimens With Avastin® And Carboplatin In Ovarian Cancer

ImmunoGen Announces Positive Findings From The FORWARD II Study Of Mirvetuximab Soravtansine Combination Regimens With Avastin® And Carboplatin In Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in...

ImmunoGen Reaches Analyst Target Price

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $10.62, changing hands for $10.84/share.

ImmunoGen Reports Recent Progress And First Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And First Quarter 2018 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.

ImmunoGen Announces Webcast Of Presentation At Deutsche Bank's 43rd Annual Health Care Conference

ImmunoGen Announces Webcast Of Presentation At Deutsche Bank's 43rd Annual Health Care Conference

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43 rd Annual Health Care Conference.

Noteworthy Friday Option Activity: IMGN, HABT, STZ

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ImmunoGen, Inc. , where a total of 19,320 contracts have traded so far, representing approximately 1.9 million underlying shares.

TheStreet Quant Rating: D (Sell)